System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Louisa von Baumgarten, MD is an expert in Neurology at LMU Klinikum (Germany). Louisa von Baumgarten has authored 176 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 2 of them ongoing. SLR score: 668 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Louisa von Baumgarten, MD LMU Klinikum Germany
668 ScienceLeadR Reputation 668

Unlock

Register Login
Network Map

Neurology

Subspecialties: Oncology - Hematology - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2008 - 2026
Source: PubMed

Ludwig-Maximilians-Universität München

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 176

Citations

Citations: 3 619 1st author: 9 Last author: 40 Unique author: 0

Main journals

Neuro Oncol 36
Eur J Nucl Med Mol Imaging 11
Blood 7
J Neurooncol 6
Neurology 6

Best Journals

J Clin Oncol 2
Cancer Cell 1
Lancet Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Allocation of TSPO-PET signals to cellular and extracellular compartments in dependence of blood-brain barrier disruption in experimental glioblastoma.
PMID 42778718 — blood-brain barrier, cells, blood, brain, neoplasms, glioblastoma		Eur J Nucl Med Mol Imaging20260
Identification of prognostically relevant residual tumor in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs. [18F]FET PET.
PMID 42693952 — brain neoplasms, neoplasms, tumor burden, glioblastoma		Neuro Oncol20260
PET RANO 1.0 vs. RANO 2.0 criteria for trial eligibility in IDH-wildtype glioblastoma: a retrospective, comparative study.
PMID 42599218 — brain neoplasms, glioblastoma		Neuro Oncol20260
Whole-body TSPO-PET reveals stage-dependent disruption of systemic immune organ interactions in glioblastoma.
PMID 42443495 — lung, positron-emission tomography, brain, neoplasms, glioblastoma, nuclear medicine		Eur J Nucl Med Mol Imaging20260
Peritumoral brain zone oxygen extraction fraction is associated with tumor Ki-67 index in untreated glioblastoma.
PMID 42428516 — brain, neoplasms, glioblastoma		Neurooncol Adv20261

Clinical Studies 6

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 4
Phase 1 1
Phase 1/Phase 2 1

By status:

Completed 2
Recruiting 2
Unknown 2

By type:

Interventional 6

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 2
multicentricup10 3

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase I II trial of meclofenamate in progressive MGMT methylated glioblastoma under temozolomide second line therapy (MecMeth NOA 24)
2024-511264-89-00 — temozolomide, glioblastoma, therapeutics		Phase 2Recruiting2022
Clinical and translational controlled study of Perampanel treatment around Surgery in patients with progressive glioblastoma (PerSurge)
2023-503938-52-00 — glioblastoma, therapeutics, artificial intelligence		Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS